The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Venetoclax combination with R- or G-CHOP in NHL: Results from the phase Ib CAVALLI trial

Mar 19, 2019

On 8 March 2019, Andrew Zelenetzfrom Memorial Sloan Kettering Cancer Center, New York, USA, and colleagues, published in Blood results from the phase Ib trial CAVALLI, which compared venetoclax plus rituximab-based or obinutuzumab-based cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; R-CHOP versusG-CHOP) chemotherapy, in non-Hodgkin lymphoma (NHL) patients.

Preclinical results have indicated that venetoclax when combined with R or G exerts synergistic effects in vitroand in xenograft models in vivo. Thus, the aim of this multicenter, phase Ib CAVALLI trial ( NCT02055820) was to assess the safety and determine a recommended dose for R-/G-CHOP chemotherapy for NHL in order to further investigate their activity in a future phase II trial. The primary endpoint was to determine the maximum tolerated dose (MTD) of venetoclax in combination with R- or G-CHOP in NHL patients. The main secondary endpoint was treatment efficacy.

Study design

  • N = 56 patients aged ≥ 18 years with histologically-confirmed B-cell NHL, previously-untreated or with one previous therapy, excluding R-CHOP.
  • Patient NHL subtypes (total cohort):
    • Follicular lymphoma (FL): n = 18
    • Diffuse large B-cell (DLBCL): n = 24
    • Other B-cell NHL: n = 14
  • Most patients (91.1%) were not previously-treated with other regimens
  • Mean patient age (range): 60.3 (37–79)
  • Male patients: 62.5%
  • Dosing:
    • Venetoclax (21-day cycles):Doses ranging from 200–800 mg once daily orally on Day 4 of cycle 1 and then on Day 1 for cycles 2–8
    • R-CHOP (Arm A; n 24):
      • R:375 mg/m 2intravenously (IV) on Day 1 for eight cycles
      • CHOP: (six or eight cycles):IV cyclophosphamide 750 mg/m 2, IV doxorubicin 50 mg/m 2, and IV vincristine b1.4 mg/m 2(with a 2.0 mg cap) on Day 1, and prednisone 100 mg daily orally on Days 1–5
    • G-CHOP (Arm B; n = 32):
      • G:1000 mg IV on Days 1, 8, and 15 of cycle 1 and on Day 1 of cycles 2–8
      • CHOP: (six or eight cycles):IV cyclophosphamide 750 mg/m 2, IV doxorubicin 50 mg/m 2, and IV vincristine b1.4 mg/m 2(with a 2.0 mg cap) on Day 1, and prednisone 100 mg/day orally on Days 1–5
    • Mandatory tumor lysis syndrome (TLS) prophylaxis was orally administered by hydration and uric-acid reducing agent (i.e. allopurinol) in the first 72 hours prior to the first venetoclax dose
    • Granulocyte-colony stimulating factor (G-CSF) was administered in later protocol versions for all CHOP cycles
  • Two-stage study:
    • Dose-escalation phase: venetoclax dose escalation. First dose in both arms was 200 mg/day for eight cycles
    • Dose and schedule selection: 3 + 3 design

Key results

  • Dose-limiting toxicities were reported in 3 out of 14 patients at the first venetoclax dose (200 mg daily). For that dosing was changed from daily to 10 days per cycle and raised to 800 mg. A further reduction to 5 days per cycle occurred at the 800 mg dose level in the G-CHOP arm
  • Median follow-up for patients achieving complete or partial response (CR/PR) at the end of treatment (range): 22 (11.4–36.4) months
  • In the intention-to-treat (ITT) population:
    • Overall response rate (ORR) for both arms: 87.5%
    • CR rates:
      • R-CHOP + venetoclax: 79.2%
      • G-CHOP + venetoclax: 78.1%
    • ORR by histological subtype across both arms:
      • DLBCL: 88.9% (all CR)
      • FL: 83.3% (CR, 75%; PR, 8.3%)
      • Other histological subtypes: 71.4% (CR, 57.1%; PR, 14.3%)
    • Median PFS:
      • R-CHOP + venetoclax: not reached
      • G-CHOP + venetoclax: not reached
    • One-year PFS rates in DLBCL patients:
      • R-CHOP + venetoclax: 70%
      • G-CHOP + venetoclax: 100%
    • One-year PFS rates in FL patients:
      • R-CHOP + venetoclax: 100%
      • G-CHOP + venetoclax: 90%
    • Pharmacokinetic data from 49 patients showed that venetoclax exposures tested at 200, 400, 600, and 800 mg were similar when co-administered with R-CHOP or G-CHOP
    • Venetoclax plasma concentrations peaked at 4–8 hours and were comparable between the two arms

Safety

  • Across both arms, the most common any grade adverse events (AEs) were:
    • Neutropenia: 57.1%
    • Nausea: 53.6%
  • No deaths due to AEs occurred
  • The most common Grade 3–4 AEs in the R-CHOP + venetoclax arm were:
    • Neutropenia: 54.2%
    • Febrile neutropenia: 33.3%
    • Thrombocytopenia: 16.7%
    • Anemia: 12.5%
  • The most common Grade 3–4 AEs in the G-CHOP + venetoclax arm were:
    • Neutropenia: 59.4%
    • Febrile neutropenia: 25.0%
    • Thrombocytopenia: 37.5%
    • Anemia: 31.3%
  • Median duration of treatment:
    • R-CHOP + venetoclax: 154 days
    • G-CHOP + venetoclax: 152 days
  • A higher percentage of patients in the R-CHOP + venetoclax arm (71.9%) than in the G-CHOP + venetoclax arm (58.3%) experienced AEs leading to venetoclax dose reduction or discontinuation
  • Patients discontinuing venetoclax treatment early: 30.3% (n = 16 patients in both arms):
    • Due to AEs: n = 16 patients
    • Due to progressive disease (PD): n = 1 patient
  • Patients unable to complete ≥ 6 CHOP cycles due to AEs:
    • R-CHOP + venetoclax: 8.3% (n = 2/24)
    • G-CHOP + venetoclax: 18.8% (n = 6/32)

Conclusions

  • Venetoclax plus R-CHOP or G-CHOP demonstrated manageable safety and promising activity in B-cell NHL patients
  • Although the MTD was not reached, the recommended dose for venetoclax in combination with R-CHOP was 800 mg (Days 4-10, cycle 1; Days 1-10, cycles 2−8)
  • R-CHOP plus venetoclax will be evaluated in first-line DLBCL patients in the phase II part of this study  
  1. Zelenetz A.D. et al.Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood . 2019 Mar 8. pii: blood-2018-11-880526. DOI: 10.1182/blood-2018-11-880526[Epub ahead of print].